This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Natus Medical Announces 2011 Third Quarter Financial Results

“In the third quarter we experienced a reduction in large capital equipment orders over $300,000, primarily in our domestic neurology business. Although some orders we expected were placed during the quarter at significantly reduced order size, other orders were not placed at all. We believe that the orders we were working on during the third quarter have not been lost, but have been merely delayed, and we expect that they will eventually be placed with Natus,” added Hawkins. “We experienced similar sales activity in late 2008 and early 2009 and then saw those delayed orders placed in following quarters.”

“We look forward to capitalizing on the opportunity that recently acquired Embla Systems brings to our neurology business as we are now a leader in the growing worldwide market for diagnostic sleep products,” added Hawkins. “We expect the Embla acquisition to be accretive to our earnings in 2012, adding approximately $0.08 to non-GAAP earnings per share.”



As of September 30, 2011, the Company had cash, cash equivalents, and short-term investments of $30.8 million, stockholders' equity of approximately $275 million, and working capital of approximately $89 million.

Financial Guidance

Natus updated its 2011 financial guidance. For the full year 2011, the Company expects to report revenue of approximately $234 million and non-GAAP earnings per share of approximately $0.48.

For the fourth quarter 2011, the Company expects to report revenue of approximately $65 million and non-GAAP earnings per share of approximately $0.15. This compares to revenue of $63.2 million and non-GAAP earnings per share of $0.24 reported in the fourth quarter of 2010.

The Company's fourth quarter and full year 2011 non-GAAP earnings per share guidance excludes amortization expense associated with acquisition-related intangible assets, which the Company expects to be approximately $5.2 million and $1.3 million for the full year and fourth quarter 2011, respectively, and which the Company expects will reduce GAAP earnings per share by approximately $0.11 and $0.03 for the full year and quarter, respectively. The non-GAAP earnings per share guidance for those periods also excludes the effects of restructuring charges that the Company expects it may incur in the fourth quarter of 2011, the amount and timing of which have not yet been determined, as well as the impact any future acquisitions might have on its results of operations.

2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.34 -65.38 -0.36%
S&P 500 2,093.02 -8.02 -0.38%
NASDAQ 4,972.8440 -9.9650 -0.20%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs